DMT is a potent psychedelic that has shown potential in reducing depression symptoms. This naturally occurring substance can be found in different animals and plants. When inhaled or ingested, this substance produces intense auditory and visual hallucinations.
Unlike other psychedelics such a psilocybin or LSD, which produce prolonged experiences, DMT’s effects are brief, which make it a more flexible and manageable therapeutic option. A new study examined the therapeutic potential of DMT and its effects on the psychological well-being of individuals.
The study used data from a pair of complementary studies that involved 30 healthy volunteers who had previously used psychedelics. This previous exposure was an important criterion for inclusion, because it helped ensure participants were familiar with the drugs and still felt safe in an altered state of consciousness.
Prior to DMT’s administration, every participant was assessed through psychiatric interviews, medical exams and physical tests to eliminate any possible risk factors. The study involved a prospective sample analysis and placebo, with 13 participants receiving a dose of DMT, which was followed by a placebo a week later. This enabled the investigators to detect any changes that could be attributed to DMT by comparing the results of both sessions.
In the prospective sample, the researchers were focused on determining the impact DMT had on psychological well-being. The investigators observed considerable improvements in symptoms of depression after DMT was administered. This, they explained, highlighted the drug’s potential as a rapid-acting agent.
They also observed a link between the intensity of the feeling of oneness with the world brought on by DMT and improvements in mental-health outcomes. This, they noted, suggested that the psychedelic experience’s qualitative aspects could play a significant role in its therapeutic potential.
In the report, Dr. Chris Timmermann, the author of the study, stated that DMT had lower scores of symptoms of depression in healthy volunteers in a similar way to LSD and psilocybin. Timmerman is the head of DMT Research Group at Imperial College London’s Centre for Psychedelic Research. Additionally, the investigators observed a considerable drop in neuroticism in the placebo-controlled trial, which suggests that DMT could have a lasting impact on personality traits linked to mental health conditions.
Despite these promising results, the investigators noted that the focus on healthy volunteers with prior psychedelic experience, DMT dosage variability and the methodological differences between the two parts of the research could limit the generalizability of the study’s results.
The researchers are now focused on better understanding the extent to which DMT can safely be administered for therapeutic purposes. Other entities such as Compass Pathways PLC. (NASDAQ: CMPS) are also making headway in studying different psychedelic compounds including psilocybin with the intent to develop therapeutic formulations from them.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com
PsychedelicNewsWire is powered by IBN
